← Juewei Food overview

Juewei Food vs CSPC Innovation Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Juewei Food Co Ltd (603517.CG)

Q3 2026
▼3▲1

Weak earnings and stalled asset sale offset buyback and dividend support

  • Profit and revenue decline, cash flow turns negative First-half net profit fell 23% to 135 million yuan and revenue dropped 10.8% to 2.515 billion yuan. Operating cash flow swung to negative 182 million yuan, a huge deterioration. This weak core business pressures the stock because it shows the company is selling less and collecting less cash.

    The interim report is the clearest evidence of fundamental weakness driving the stock down.

  • Saifeiya stake sale hits payment snag The buyer of ST Juewei's 24.17% stake in loss-making Saifeiya missed the first payment deadline. The 84.58 million yuan exit is now uncertain, meaning the company may stay tied to a long-time money-loser and not get the cash it expected.

    This is a new negative event that threatens a planned cash inflow and adds uncertainty.

  • More related-party deals with a loss-making associate ST Juewei raised its 2026 related-party transaction quota by 25 million yuan, all tied to Sichuan Liaoji, an associate with negative net assets and a first-half loss. This raises concerns about cash being diverted to a struggling partner while the company's own finances weaken.

    It shows a new governance and capital-allocation risk that can weigh on investor confidence.

  • Buyback and dividend return cash to shareholders ST Juewei is buying back 100-200 million yuan of stock and paying a 0.25 yuan per share dividend. By September 30 it had already repurchased about 8.5 million shares for roughly 100 million yuan. These actions support the share price by reducing shares outstanding and returning cash.

    These are the main positive forces offsetting the weak earnings and asset-sale problems.

September 2026
▼3▲1

Weak earnings and stalled asset sale offset buyback and dividend support

  • Profit and revenue decline, cash flow turns negative First-half net profit fell 23% to 135 million yuan and revenue dropped 10.8% to 2.515 billion yuan. Operating cash flow swung to negative 182 million yuan, a huge deterioration. This weak core business pressures the stock because it shows the company is selling less and collecting less cash.

    The interim report is the clearest evidence of fundamental weakness driving the stock down.

  • Saifeiya stake sale hits payment snag The buyer of ST Juewei's 24.17% stake in loss-making Saifeiya missed the first payment deadline. The 84.58 million yuan exit is now uncertain, meaning the company may stay tied to a long-time money-loser and not get the cash it expected.

    This is a new negative event that threatens a planned cash inflow and adds uncertainty.

  • More related-party deals with a loss-making associate ST Juewei raised its 2026 related-party transaction quota by 25 million yuan, all tied to Sichuan Liaoji, an associate with negative net assets and a first-half loss. This raises concerns about cash being diverted to a struggling partner while the company's own finances weaken.

    It shows a new governance and capital-allocation risk that can weigh on investor confidence.

  • Buyback and dividend return cash to shareholders ST Juewei is buying back 100-200 million yuan of stock and paying a 0.25 yuan per share dividend. By September 30 it had already repurchased about 8.5 million shares for roughly 100 million yuan. These actions support the share price by reducing shares outstanding and returning cash.

    These are the main positive forces offsetting the weak earnings and asset-sale problems.

Latest
▼3▲1

Weak earnings and stalled asset sale offset buyback and dividend support

  • Profit and revenue decline, cash flow turns negative First-half net profit fell 23% to 135 million yuan and revenue dropped 10.8% to 2.515 billion yuan. Operating cash flow swung to negative 182 million yuan, a huge deterioration. This weak core business pressures the stock because it shows the company is selling less and collecting less cash.

    The interim report is the clearest evidence of fundamental weakness driving the stock down.

  • Saifeiya stake sale hits payment snag The buyer of ST Juewei's 24.17% stake in loss-making Saifeiya missed the first payment deadline. The 84.58 million yuan exit is now uncertain, meaning the company may stay tied to a long-time money-loser and not get the cash it expected.

    This is a new negative event that threatens a planned cash inflow and adds uncertainty.

  • More related-party deals with a loss-making associate ST Juewei raised its 2026 related-party transaction quota by 25 million yuan, all tied to Sichuan Liaoji, an associate with negative net assets and a first-half loss. This raises concerns about cash being diverted to a struggling partner while the company's own finances weaken.

    It shows a new governance and capital-allocation risk that can weigh on investor confidence.

  • Buyback and dividend return cash to shareholders ST Juewei is buying back 100-200 million yuan of stock and paying a 0.25 yuan per share dividend. By September 30 it had already repurchased about 8.5 million shares for roughly 100 million yuan. These actions support the share price by reducing shares outstanding and returning cash.

    These are the main positive forces offsetting the weak earnings and asset-sale problems.

CSPC Innovation Pharmaceutical Co Ltd Class A (300765.CS)

Q3 2026
▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

  • Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.

    The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.

  • SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.

    This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.

  • Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.

    These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

August 2026
▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

  • Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.

    The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.

  • SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.

    This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.

  • Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.

    These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

Latest
▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

  • Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.

    The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.

  • SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.

    This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.

  • Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.

    These regulatory and clinical steps expand the pipeline and signal more near-term product launches.